학술논문

Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation.
Document Type
article
Source
Genes & development. 29(6)
Subject
Tumor Cells
Cultured
Animals
Humans
Mice
Carcinoma
Pancreatic Ductal
Pancreatic Neoplasms
Cell Transformation
Neoplastic
Azepines
Triazoles
DNA Helicases
Nuclear Proteins
Transcription Factors
Gene Expression Regulation
Neoplastic
Proto-Oncogene Proteins p21(ras)
SOX9 Transcription Factor
Brg1
EMT
IPMN
Kras
dedifferentiation
pancreatic cancer
Rare Diseases
Stem Cell Research
Cancer
Pancreatic Cancer
Digestive Diseases
Genetics
2.1 Biological and endogenous factors
Aetiology
Biological Sciences
Medical and Health Sciences
Psychology and Cognitive Sciences
Developmental Biology
Language
Abstract
Pancreatic ductal adenocarcinoma (PDA) develops predominantly through pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN) precursor lesions. Pancreatic acinar cells are reprogrammed to a "ductal-like" state during PanIN-PDA formation. Here, we demonstrate a parallel mechanism operative in mature duct cells during which functional cells undergo "ductal retrogression" to form IPMN-PDA. We further identify critical antagonistic roles for Brahma-related gene 1 (Brg1), a catalytic subunit of the SWI/SNF complexes, during IPMN-PDA development. In mature duct cells, Brg1 inhibits the dedifferentiation that precedes neoplastic transformation, thus attenuating tumor initiation. In contrast, Brg1 promotes tumorigenesis in full-blown PDA by supporting a mesenchymal-like transcriptional landscape. We further show that JQ1, a drug that is currently being tested in clinical trials for hematological malignancies, impairs PDA tumorigenesis by both mimicking some and inhibiting other Brg1-mediated functions. In summary, our study demonstrates the context-dependent roles of Brg1 and points to potential therapeutic treatment options based on epigenetic regulation in PDA.